AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

New Therapeutic Focus for Ichthyosis or EDDs

Description

The talk emphasizes the complexity involved in managing ichthyosis and other epithelial derived disorders (EDDs) due to their diverse clinical manifestations across different ages. Despite long-standing knowledge about these diseases, there remains a lack of consensus guidelines for treatment, particularly for newborns. Recent studies led by Dr. Reagan Hunt and Dr. Keith Cho aim to establish evidence-based guidelines and improve care. The discussion highlights the use of topical retinoids, with recent clinical trials demonstrating some efficacy in treating lamellar ichthyosis and X-linked ichthyosis, although a phase three trial showed no significant overall improvements. Future therapeutic strategies focus on targeted therapies, including biologics to reduce inflammation and various replacement therapies, such as enzyme or lipid replacement. Innovative approaches such as gene replacement and editing also show promise by potentially correcting underlying genetic defects. An understanding of genetic mutations aids in categorizing patients and predicting clinical outcomes, essential for developing tailored treatments. Despite ongoing challenges and varied patient responses to therapies, the integration of multiple treatment modalities may provide comprehensive management of these complex conditions.

View more

Conclusions

  • The complexity of managing ichthyosis varies significantly by the age and specific characteristics of patients, necessitating tailored treatment approaches.
  • Current research is focusing on developing consensus guidelines for treating congenital ichthyosis in neonates.
  • A phase 2/3 clinical trial of topical isotretinoin for treating lamellar ichthyosis and X-linked ichthyosis showed some positive efficacy in phase 2 but failed to demonstrate significant results in phase 3.
  • Despite the phase 3 trial results, some participants experienced improvements potentially due to a placebo response, indicating a floor effect.
  • Topical isotretinoin appears safe for use even on extensive skin areas due to low systemic absorption, offering a new option for patients.
  • Ongoing and future treatment strategies are focusing on targeted therapies based on genetic mutation profiles to improve treatment effectiveness and patient outcomes.
  • Biologics and gene therapies are being explored as promising alternatives for managing ichthyosis and epidermal differentiation disorders (EDDs), highlighting the shift towards addressing underlying genetic causes.
  • Combination therapies may provide more holistic and effective management of ichthyosis by addressing both symptoms and underlying causes.
  • Further studies are essential to refine treatment protocols and understand the complexities of ichthyosis and its subtypes.
  • Clin Cosmet Investig Dermatol. 2023 Sep 11;16:2473-2479. Lilly et al.
  • Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, Ungar B, Kunjravia N, Friedland R, Peng X, Zheng X, Estrada YD, Krueger JG, Choate KA, Suárez-Fariñas M, Guttman-Yassky E. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139:152-65.
  • Paller AS. Pathogenesis-based therapy with repurposed biologics for monogenic inflammatory skin disorders. JAMA Dermatol. 2020;156:839-41.
  • Luchsinger V, Toh K, Pavlidis P. Secukinumab therapy for Netherton syndrome. JAMA Dermatol. 2020 Aug 1;156(8):907-911.
  • Bornholdt J, et al. Mutations in NSDHL gene. J Med Genet 2005;42:e17.
  • Cattaneo C, et al. Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells. Mol Ther. 2024 Feb 7;32(2):372-383.
  • Michael Wilschanski, M.D., Yaacov Yahav, M.D., Yasmin Yaacov, B.Sc., Hannah Blau, M.D., Lea Bentur, M.D., Joseph Rivlin, M.D., Micha Aviram, M.D., Tali Bdolah-Abram, M.Sc., Zsuzsa Bebok, M.D., Liat Shushi, M.Sc., Batsheva Kerem, Ph.D., and Eitan Kerem, M.D. Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations. N Engl J Med. [year].